John Overdeck’s vTv Therapeutics VTVT Stock Holding History

John Overdeck’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$432K	Buy	+11,486	New	+$398K	﹤0.01%	4264
2021 Q3	–	Sell	-3,692	Closed	-$337K	–	4761
2021 Q2	$337K	Sell	3,692 -5,745	-61%	-$582K	﹤0.01%	3422
2021 Q1	$1.06M	Buy	+9,437	New	+$927K	﹤0.01%	2255
2020 Q4	–	Sell	-12,562	Closed	-$889K	–	3806
2020 Q3	$889K	Buy	12,562 +990	+9%	+$87K	﹤0.01%	1841
2020 Q2	$1.04M	Buy	11,572 +4,815	+71%	+$475K	0.01%	1517
2020 Q1	$516K	Buy	6,757 +4,549	+206%	+$437K	﹤0.01%	1905
2019 Q4	$150K	Buy	+2,208	New	+$134K	﹤0.01%	3476

Other funds holding VTVT

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

John Overdeck's VTVT Position: Q2 2026 in Review

John Overdeck opened a new position in vTv Therapeutics (VTVT) in Q2 2026: 11,486 shares worth $432K. The stake represents ﹤0.01% of the portfolio and ranks #4264 among its holdings. This is a return to the name: John Overdeck previously reported a position in VTVT as recently as Q2 2021.

John Overdeck first reported a position in VTVT in Q4 2019 and has held it in 7 quarters since. The position peaked at $1.06M in Q1 2021. 45 funds tracked by Wall St. Rank hold VTVT as of Q2 2026.

John Overdeck held 11,486 shares of vTv Therapeutics worth $432K as of Q2 2026.
vTv Therapeutics was a new John Overdeck position in Q2 2026.
vTv Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4264 holding.
John Overdeck first reported a position in vTv Therapeutics in Q4 2019 and has held it in 7 quarters since.
John Overdeck's vTv Therapeutics position peaked at $1.06M in Q1 2021.
45 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.